REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

RGX-202 demonstrating consistent evidence of positively changing disease trajectory for DuchenneAll dose level 2 participants exceeded external natural history controls on all functional measuresBiomarker data demonstrate consistent, robust microdystrophin expression and transduction levels across all treated agesOne new participant aged…

REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy

New data reveals RGX-202 gene therapy shows significant improvements in Duchenne muscular dystrophy patients, enhancing disease management and safety.

Regenxbio says Duchenne gene therapy improved motor skills in five patients

Regenxbio announced the latest functional outcomes of five children with Duchenne muscular dystrophy who received its gene therapy. The muscle disease biotech said on Thursday that all five patients saw improvements ...

Regenxbio reports positive interim data from Phase 1/2 microdystrophin gene therapy trial

Regenxbio shared positive data from the AFFINITY DUCHENNE trial of RGX-202.  In addition to robust microdystrophin expression, Regenxbio reported functional benefits at 9 and 12 months after treatment for all of the first 5 participants receiving the pivotal dose (2E14 GC/kg), aged 6-12 years at dosing.  You can learn more here and during a webinar [REGISTER HERE], CureDuchenne is hosting with Regenxbio on Wednesday, June 11th at 1 pm ET. The po…